Home Newsfeeds Goldman Sachs Maintains Buy on Iovance Biotherapeutics, Lowers Price Target to $18

Goldman Sachs Maintains Buy on Iovance Biotherapeutics, Lowers Price Target to $18

Goldman Sachs analyst Madhu Kumar maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and lowers the price target from $64 to $18.

byBenzinga Newsdesk

July 1, 2022

1 minute read

Goldman Sachs analyst Madhu Kumar maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and lowers the price target from $64 to $18.

MKS Instruments Analysts Await Elaboration On Ransomware Impact Post Q4 Results

By Anusuya Lahiri

February 28, 3:32 PM

Benchmark analyst Mark Miller had a Hold rating on MKS Instruments, Inc (NASDAQ:MKSI). For its 4Q22, MKS reported adjusted EPS of $2.00…

MKSI

Microsoft’s Astonishing Comeback – Its Stunning 974% Decade Growth and the Promise of More to Come!

By Zaheer Anwari

April 2, 3:12 PM

Over the last decade, Microsoft's stock has demonstrated substantial growth, rising 974%, highlighting its potential as a stable investment for long-term portfolios. The stock is currently stabilizing at a $420 support level, suggesting the possibility of another sustained upward trend.

MSFT

Tesla Soars 10% Amid Musk’s China Visit, Lucid Slumps On Stock Sale, Ford-Uber’s Win-Win Partnership And More: Biggest EV Stories Of The Week

By Shanthi Rexaline

June 3, 9:14 AM

Electric vehicle stocks closed the week ending May 19 on a mixed note, with market leader Tesla, Inc.…

BYDDF

News

China’s AI Advancements Accelerate Humanoid Robot Development: What You Need To Know

By Benzinga Neuro

May 8, 5:30 AM

China is witnessing a rapid advancement in the field of artificial intelligence, which is significantly accelerating the development of humanoid robots.

BIDU

Goldman Sachs Maintains Buy on Iovance Biotherapeutics, Lowers Price Target to $18

Related Posts

MKS Instruments Analysts Await Elaboration On Ransomware Impact Post Q4 Results

Microsoft’s Astonishing Comeback – Its Stunning 974% Decade Growth and the Promise of More to Come!

Tesla Soars 10% Amid Musk’s China Visit, Lucid Slumps On Stock Sale, Ford-Uber’s Win-Win Partnership And More: Biggest EV Stories Of The Week

China’s AI Advancements Accelerate Humanoid Robot Development: What You Need To Know